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Human pluripotent stem cells (hPSCs), such as human embryonic stem cells (hESCs) and human induced
pluripotent stem cells (hiPSCs), are leading candidate cells as raw materials for cell therapy products,
because of their capacity for pluripotent differentiation and unlimited self-renewal. hPSC-derived
products have already entered the scope of clinical application. However, the assessment and control of
their tumorigenicity remains to be a critical challenge. Sensitive detection of the pluripotent cellular
impurities is necessary for the safety and quality control of the hPSC-derived products. In the present
study, we established a sensitive assay for detection of the residual undifferentiated hiPSCs in car-
diomyocytes, using droplet digital PCR (ddPCR). The ddPCR method with a probe and primers for LIN28
signiﬁcantly detected as low as 0.001% undifferentiated hiPSCs in primary cardiomyocytes, which is
equivalent to the ratio of a single hiPSC to 1  105 cardiomyocytes. The ddPCR also showed that LIN28
expression is extremely low in human tissues including liver, heart, pancreas, kidney, spinal cord, corneal
epithelium and lung. These results suggest that the ddPCR method targeting LIN28 transcripts is highly
sensitive and useful for the quality assessment of various cell therapy products derived from hPSCs.
© 2015, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).1. Introduction
Human pluripotent stem cells (hPSCs) such as human embry-
onic stem cells (hESCs) and human induced pluripotent stem cells
(hiPSCs) have the ability to differentiate into a variety of cell types
and undergo numerous cell division cycles while maintaining their
cellular identity. Because of their pluripotency and self-renewalerapeutic Products, National
se Society for Regenerative
ative Medicine. Production and hoproperty, it has been expected that hPSCs will provide new sour-
ces for robust and continuous production of many cell and tissue
types for regenerative medicine and cell therapy. As previously
reported, many attempts are currently underway to differentiate
hPSCs into various tissues [1,2]. Cell therapy using hPSCs has
already entered the scope of clinical application. Clinical trials using
hESC-derived retinal pigment epithelial (RPE) cells have been
initiated to treat patients with Stargardt's disease and the dry type
of age-related macular degeneration [3]. Clinical research using
autologous hiPSC-derived RPE for the wet type of age-related
macular degeneration has also started in Japan.
One of the most important issues in the development of a safe
cell therapy product derived from hPSCs is ensuring that the ﬁnal
product does not form tumors after implantation [4]. The productssting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Fig. 1. Detection of undifferentiated hiPSCs in primary cardiomyocytes using the
LIN28/qRT-PCR method. (A) LIN28, NANOG, REX1, SOX2, OCT3/4, KLF4 and c-MYC relative
mRNA expression in cardiomyocytes was determined using qRT-PCR analysis. (B) qRT-
PCR analysis of hiPSCs spiked into three lots of primary cardiomyocytes. Single-cell
hiPSCs (0.1%, 1  103 cells; 0.01%, 1  102 cells; 0.001%, 1  101 cells) were spiked
into 1  106 primary cardiomyocytes, and total RNA was isolated from the mixed cells.
All values are expressed as mRNA levels relative to those in undifferentiated hiPSCs.
hCM: human cardiomyocyte. The expression levels of target genes were normalized to
those of the GAPDH transcript. Results are presented as the mean ± standard deviation
(n ¼ 3).
T. Kuroda et al. / Regenerative Therapy 2 (2015) 17e2318derived from hPSCs may contain residual undifferentiated cells that
eventually proliferate and form a teratoma [5]. The required cell
number of hPSC-derived products varies depending on the dis-
eases. In the case of RPE cell transplantation, approximately 5 104
RPE cells is thought to be required for retinal degeneration diseases.
We have previously reported that qRT-PCR successfully detects
0.002% residual undifferentiated cells in hiPSC-derived RPE cells
using LIN28 as a target gene [6]. The sensitivity of this assay is
sufﬁcient for the quality control hiPSC-derived RPE cells. However,
at least 109 cardiomyocytes would be needed for transplant into
one patient with heart failure [7], indicating that testing hPSC-
derived cardiomyocytes products using the LIN28/qRT-PCR
method may lead to false-negative test results. For the quality
control of hPSC-derived cardiomyocytes, the detection of pluripo-
tent cellular impurities in the products needs to be as sensitive as
possible.
Recently, a new PCR format called droplet digital PCR (ddPCR)
that directly quantiﬁes DNA/mRNA copies has been developed. The
ddPCR takes advantage of water-in-oil droplets to divide a 20 mL
mixture of sample and reagents into ~20,000 droplets. For droplets
that contain template, speciﬁc cleavage of TaqMan probes gener-
ates a strong ﬂuorescence signal. An automated droplet ﬂow-
cytometer reads each set of droplets after PCR, and droplets are
assigned as positive or negative based on their ﬂuorescence
amplitude. The number of positive and negative droplets in each
channel is used to calculate the concentration of the target nucleic
acid [8]. This assay can avoid bias that arises from inefﬁcient target
gene ampliﬁcation using qRT-PCR [9,10]. In addition, ddPCR effec-
tively enriches template concentrations in partitions and allows for
the more sensitive detection of rare targets compared with qRT-
PCR [8].
In this study, we established a highly sensitive assay for detec-
tion of residual undifferentiated hiPSCs in cell therapy products.
The LIN28/qRT-PCR method was shown to detect 0.01% undiffer-
entiated hiPSCs spiked into primary cardiomyocytes. We also
determined that the LIN28/ddPCRmethod is able to detect as low as
0.001% undifferentiated hiPSCs in primary cardiomyocytes, which
is equivalent to a single hiPSC contained in 1 105 cardiomyocytes.
2. Results
2.1. Detection of undifferentiated hiPSCs in cardiomyocytes using
the LIN28/qRT-PCR method
The marker genes for detecting trace amount of residual un-
differentiated cells in cell therapy products should be highly
expressed in hPSCs but be strongly silenced in differentiated cells.
We ﬁrst ascertained whether LIN28 mRNA is a superior marker for
detecting residual undifferentiated cells in hiPSC-derived car-
diomyocytes. To identify highly selective markers for undifferen-
tiated hiPSCs, we compared MYC (c-MYC), KLF4, POU5F1 (OCT3/4),
SOX2, REX1, NANOG and LIN28A (LIN28) mRNA levels in hiPSCs and
primary cardiomyocytes. REX1, NANOG and LIN28 gene expressionwas not detected in primary cardiomyocytes (Fig. 1A). However, in
hiPSCs, the Ct values of REX1, NANOG and LIN28 was 34.2, 25.2 and
22.6, respectively (data not shown). Thus, the LIN28 expression
level was drastically changed between primary cardiomyocytes and
hiPSCs. These results indicated that LIN28 was the most sensitive
marker of residual undifferentiated cells in hiPSC-derived car-
diomyocytes among seven candidate marker genes, as well as in
hiPSC-derived RPE cells [6].
To deﬁne the minimum number of hiPSCs that may be detected
using the LIN28/qRT-PCR method, we spiked 1  104 (1%), 1  103
(0.1%), 1  102 (0.01%) and 1  10 (0.001%) hiPSCs into 1  106
primary cardiomyocytes. Total RNA isolated from these mixed cells
was subjected to the LIN28/qRT-PCR method, and LIN28 mRNA
signals of 0.1% and 0.01% were detected for spiked hiPSCs in a dose-
dependent manner, but 0.001% spiked hiPSCs in the sample were
not detectable (Fig. 1B), indicating that the LIN28/qRT-PCR method
is able to detect at least 0.01% residual undifferentiated hiPSC
contamination in cardiomyocytes.
To evaluate residual undifferentiated hiPSCs in the ﬁnal prod-
ucts, we differentiated hiPSCs into cardiomyocytes using an in vitro
differentiation protocol, as previously described [11]. The GSK3
inhibitor CHIR99021 was added on day 0e1 to activate Wnt
signaling, and then Wnt production-4 (IWP4) was added on day
3e5 to inhibit Wnt signaling (Fig. 2A). Beating cells were found on
day 8e9 and they were broadly spread out by day 15 after car-
diomyocyte induction (Movie S1). Gene-expression analysis using
qRT-PCR revealed that TNNT2, GATA4, NKX2.5 andMYH6, which are
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Fig. 2. Detection of undifferentiated hiPSCs in hiPSC-derived cardiomyocytes using the LIN28/qRT-PCR method. (A) Schematic diagram of culture procedure for cardiomyocyte. (B)
qRT-PCR analysis of cardiomyocyte markers, TNNT2, GATA4, NKX2.5 and MYH6. Total RNA was isolated from hiPSC-derived cardiomyocytes (black bar) and primary cardiomyocytes
(white bar). The mRNA levels are shown relative to those in primary cardiomyocytes. (C) Flow cytometry analysis of TNNT2 in hiPSCs (red), and hiPSC-derived cardiomyocytes at day
20 (blue). (D) LIN28 expression in hiPSCs differentiating into cardiomyocytes (d10 and d20). LIN28 mRNA levels are shown relative to that in undifferentiated hiPSCs. hCM: human
cardiomyocyte. The expression levels of target genes were normalized to those of the GAPDH transcript. Results are presented as the mean ± standard deviation (n ¼ 3).
T. Kuroda et al. / Regenerative Therapy 2 (2015) 17e23 19speciﬁc markers for cardiomyocytes, were equally well expressed
both in the hiPSC-derived cardiomyocytes and human heart
(Fig. 2B). In addition, ﬂow cytometry analysis showed that 91.4% of
differentiated cells at day 20 were TNNT2-positive (Fig. 2C). These
results indicate that hiPSCs were differentiated into car-
diomyocytes at day 20. Total RNA extracted from differentiated cells
(day 10 and 20) was subjected to the LIN28/qRT-PCR method. LIN28
mRNA levels continuously decreased during the differentiation
process, to 1.2% of that of hiPSCs at day 20 (Fig. 2D).
Supplementary video related to this article can be found at
http://dx.doi.org/10.1016/j.reth.2015.08.001.2.2. Detection of undifferentiated hiPSCs in cardiomyocytes using
the LIN28/ddPCR method
ddPCR has recently been shown to enable the precise quantiﬁ-
cation of target nucleic acids in samples. To establish a highly
sensitive assay for detection of residual undifferentiated hiPSCs in
the ﬁnal product, we employed ddPCR (the LIN28/ddPCR method)
as a substitute for qRT-PCR in this study. The ddPCR system mea-
sures ﬂuorescence intensities of droplets after completing all
thermal cycling. The copy number of target genes is determined
based on the number of ﬂuorescent-positive and -negative droplets
LI
N
28
 m
R
N
A
 c
op
ie
s
0
1000
2000
3000
4000
5000
6000
7000
0.5 ng 0.05 ng
14,000
12,000
10,000
8,000
6,000
4,000
2,000
0
FA
M
 A
m
pl
itu
de
0.1% 0.01% 0.001% A B C
hCM 3LotsHiPSCs spiked inhCM Lot. A
1,000
100
10
0.1
1
10,000
0.1% 0.01% 0.001% A B C
LI
N
28
 m
R
N
A
 c
op
ie
s/
 5
0 
ng
 o
f R
N
A
6.0 copies (LLOD)
hCM 3LotsHiPSCs spiked inhCM Lot. A
A
B
C
HiPSC total RNA
Fig. 3. Detection of undifferentiated hiPSCs in primary cardiomyocytes using the
LIN28/ddPCR method. (A) The copy number of LIN28 mRNA in 0.5 and 0.05 ng total
RNA of hiPSC was investigated by ddPCR. (B) The copy number of LIN28mRNA in 50 ng
total RNA of hiPSC-spiked cardiomyocytes and three lots of primary cardiomyocytes
were investigated by ddPCR. Dots indicate the ﬂuorescence intensity of the droplets.
Droplets were assigned “positive” or “negative” based on their ﬂuorescence amplitude.
(C) Raw droplet data shown in (B) were quantiﬁed as LIN28 mRNA copies. These
samples used in Fig. 1B and Fig. 3B/C were same ones. hCM: human cardiomyocyte.
Results are presented as the mean ± standard deviation (n ¼ 3).
T. Kuroda et al. / Regenerative Therapy 2 (2015) 17e2320in a sample well. We ﬁrst determined the optimal experimental
conditions for the newly designed assay. We tested 6 different
probe and primer sets to select an optimum one (Table S2) and also
determined their optimum annealing temperature (Fig. S1). We
then selected LIN28-1 and 64 C as the probe and primer set and an
annealing temperature, respectively, for the following experiments
with ddPCR.
ddPCR has an advantage because it provides an absolute number
of LIN28mRNA copies present in the sample. To estimate the LIN28
mRNA copy number present in a single hiPSC, we determined the
LIN28 mRNA copy number in 0.5 ng and 0.05 ng total RNA isolated
from hiPSCs by the LIN28/ddPCR method. There were 6000 ± 380
copies of LIN28 mRNA obtained from 0.5 ng RNA, and 572 ± 42
copies of LIN28mRNA obtained from 0.05 ng of RNA (Fig. 3A). Since
500 ng of RNAwas obtained from 1 105 hiPSCs, approximately 60
copies of LIN28 mRNA were estimated to exist in one hiPSC.
Therefore, 1 copy of LIN28 mRNA per 50 ng of RNA is calculated to
be equivalent to 0.0002% hiPSCs contamination. The theoretical
limit of detection for the LIN28/ddPCR method is estimated as
0.0002% (one cell in 500,000 cell).
To examine the detection limit of the LIN28/ddPCR method, we
analyzed the LIN28 mRNA copy number of the hiPSCs-spiked pri-
mary cardiomyocytes with the LIN28/ddRT-PCR method. The 0.1%,
0.01% and 0.001% hiPSC-spiked samples contained 1495.3, 91.3 and
12.4 copies of LIN28 mRNA per sample (50 ng of total RNA),
respectively. On the other hand, three lots of primary car-
diomyocyte samples showed 1.7 ± 1.3 copies of LIN28 mRNA. The
lower limit of detection (LLOD, LLOD ¼ mean þ 3.3  SD [12]) was
6.0 copies (Fig. 3B, C), when primary cardiomyocyte samples were
employed as the negative control. These results indicate that the
LIN28/ddPCR method is able to detect 0.001% hiPSCs spiked into
primary cardiomyocytes. The LLOD in Fig. 3B and C was the same as
those based on the data from two other lots of cardiomyocytes
(Fig. S2).
Finally, to conﬁrm the versatility of LIN28 mRNA as a high sen-
sitive marker of residual undifferentiated hiPSCs, we measured
background expression levels of LIN28 mRNA in various types of
human tissues using ddPCR. Since a high signal to noise ratio is
commonly required for sensitive detection, the lower expression of
LIN28 mRNA in normal tissues would be preferable as the back-
ground. As expected, LIN28 mRNA levels were extremely low in all
of liver, heart, pancreas, kidney, spinal cord, corneal epithelium and
lung samples detecting with LIN28/ddPCR methods. Mean copy
numbers of all these tissues were less than 1.5 copies per sample
(Fig. 4A), which was consistent with the results with car-
diomyocytes (Fig. 3B, C). To compare the versatility of LIN28mRNA
with other genes, we further measured the NANOG, OCT3/4 and
SOX2 mRNA levels in these normal human tissues using qRT-PCR.
Small amounts of NANOG, OCT3/4 and SOX2 mRNA were present
in the tissues, except for NANOG expression in heart and liver
(Fig. 4B). These results suggest that LIN28 mRNA is a suitable
marker to detect residual undifferentiated hiPSCs in products and
that the LIN28/ddPCR method is applicable to the quality control of
hiPSC-derived cell therapy products, i.e. hepatocytes, car-
diomyocytes, pancreatic b-cells, kidney cells, spinal cord, corneal
epithelium and lung cells.
3. Discussion
For the safety and quality of cell therapy products derived from
hPSCs, the level of residual undifferentiated cells that have
tumorigenic potential is one of the critical attributes. Therefore, it is
necessary to develop highly sensitive, validated assays for the
detection of the pluripotent cellular impurities. In this study, we
developed a novel, highly sensitive in vitro assay to detect residualundifferentiated hiPSCs in cardiomyocytes using ddPCR. The ddPCR
assay appeared to detect as few as 0.001% undifferentiated iPSCs
spiked into primary cardiomyocytes using LIN28 as a target gene.
In the previous study, we reported that a qRT-PCR assay suc-
cessfully detected 0.002% residual undifferentiated cells in hiPSC-
derived RPE cells using LIN28 as a target gene [6]. In the present
study, we modiﬁed this method to detect residual undifferentiated
hiPSCs in cardiomyocytes. When detecting a trace amount of
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Fig. 4. Detection of LIN28mRNA in various types of human tissues using the LIN28/ddPCR method. (A) Absolute quantiﬁcation of LIN28 mRNA copy number in normal tissues using
ddPCR. Total RNA (50 ng) was analyzed. (B) qRT-PCR analysis of normal tissues. Total RNA (50 ng) was analyzed. LIN28, NANOG, OCT3/4 and SOX2 mRNA levels are shown as
expression relative to those in undifferentiated hiPSCs. The expression levels of target genes were normalized to those of the ribosomal RNA. Results are presented as the
mean ± standard deviation of three different lots of each tissue.
T. Kuroda et al. / Regenerative Therapy 2 (2015) 17e23 21cellular impurities in hiPSC-derived products by expression anal-
ysis of pluripotency marker genes, it is important that their
expression levels are sufﬁciently low in normal somatic cells of
interest. As in the case of RPE cells, we found that the LIN28mRNA
expression was suppressed in primary cardiomyocytes (Fig. 1B). In
addition, we also conﬁrmed the expression of LIN28, NANOG, OCT3/
4 and SOX2 in normal tissues (human liver, heart, pancreas, kidney,
spinal cord, corneal epithelium and lung) using qRT-PCR. NANOG,OCT3/4 and SOX2mRNAwas present in most of these tissues in low
amounts, whereas LIN28 expression was totally absent in all of the
tissues examined (Fig. 4B). These results indicate that LIN28 is a
useful marker for detecting residual hiPSCs in cell therapy products.
The ddPCR technology avoids ampliﬁcation efﬁciency bias,
which is observed with matrix-linked inhibition that occurs with
qRT-PCR. Therefore, ddPCR is more sensitive than qRT-PCR and can
detect rare targets, thus providing accurate data [13,14]. In the
T. Kuroda et al. / Regenerative Therapy 2 (2015) 17e2322present study, we have compared qRT-PCR with one-step ddPCR,
using biological samples that have a low target copy number.
ddPCR detected LIN28 signals when as little as 0.001% hiPSCs were
spiked into cardiomyocytes, but this was not detected using qRT-
PCR, namely the sensitivity of ddPCR is ten times higher than that
of qRT-PCR in this assay (Figs. 1B and 3B). However, reaction con-
ditions with ddPCR should be carefully titrated to optimize the new
platform. First, depending on the design of probes and primers, the
number of positive drops and their ﬂuorescence intensity were
impacted. The ﬂuorescence intensity was also affected by the
annealing temperature, but amplicon size had no effect (Fig. S1,
Table S2). Second, determination of the threshold to distinguish
between positive and negative droplets is critical to accurately
quantify target gene copy number using ddPCR [15]. We measured
water, which was used as the negative control, in triplicate to
determine the threshold between the positive and negative
droplets.
The one-step ddPCR technology provides an absolute count of
target mRNA copies per input sample as described. Absolute
quantiﬁcation provided from the LIN28/ddPCRmethod showed that
limit of detection is theoretically 0.0002% hiPSCs contained in cell
samples (Fig. 3A). This sensitivity would not be sufﬁcient for
transplant of cardiomyocytes because at least 109 cardiomyocytes is
thought to be necessary for one patient with heart failure [7]. This
indicates that tests of hPSC-derived cardiomyocytes products using
the current in vitro detection methods may still lead to false-
negative test results. However, to date and to our knowledge, the
LIN28/ddPCR method in the present study is the most sensitive
in vitro methods to quantitatively detect a trace amount of plurip-
otent cellular impurities in normal somatic cells. The LIN28/ddPCR
method can be applicable at least to quality assessment and process
validation of hPSC-derived products (or their intermediate prod-
ucts). Namely, although “Negative in the LIN28/ddPCR test”may not
directly indicate the “safety”, the negative result can be one of
critical “quality” attributes to demonstrate the absence a certain
amount of hPSCs. The problems with sensitivity may be resolved
using a combination of a new, highly efﬁcient culture ampliﬁcation
method for the undifferentiated hPSCs contained in cell therapy
products [16] and the LIN28/ddPCR method. It should be also noted
that the theoretical limit of detection would be different in cell
types, due to variation of estimated total RNA contents per cell.
Moreover, the LLOD for the LIN28/ddPCR method may vary, if the
copy numbers of LIN28 are different between hiPSC lines. However,
the LIN28 mRNA numbers were similar across all the hiPSC lines
examined (253G1, 201B7, R-1A, R-2A, R-12A) (Fig. S3), indicating
that the LLOD of LIN28/ddPCR method is quite constant among
hiPSC lines.
There are several in vivo and in vitro assays available for detec-
tion of pluripotent cellular impurities [17]. In vivo tumorigenicity
tests using severely immunodeﬁcient mice are suggested to detect
a small amount of undifferentiated hPSCs. Kanemura et al. [18]
reported that in vivo tumorigenicity tests using NOD/Shi-scid
IL2rgnull (NOG) mice can detect tumors derived from as few as
10 hiPSCs. Although the in vivo tumorigenicity assay is costly and
time-consuming, it can directly analyze tumor formation. On the
other hand, our in vitro LIN28/ddPCR method is simple and rapid
enough to obtain the results prior to the clinical application of the
ﬁnal product. However, in vitro LIN28/ddPCR method indirectly
detects undifferentiated cells. Namely, it cannot determine
whether completely undifferentiated hiPSCs or partially differen-
tiated hiPSCs are contained in products. The hPSC-detecting assays
should be chosen to assess the safety of hPSC-derived products, and
consideration should be given to the limitations of each test. The
overall safety of each hPSC-derived product should be estimated
based on the results of appropriate the hPSC-detecting assays.Moreover, it is necessary to understand that residual undifferenti-
ated hiPSC is not only a cause of the tumorigenicity. Tumorigenicity
studies for hPSC-derived products should examine not only the
existence of residual undifferentiated pluripotent cells, but also the
existence of tumorigenic transformants, and whether the trans-
plant forms tumor in microenvironments at the site of trans-
plantation [17].
The LIN28/ddPCR method is the most sensitive in vitro assay for
detecting undifferentiated hiPSCs at present, and has the potential
to be widely applied to quality assessment of hPSC-derived prod-
ucts. We expect our ﬁndings to assist with the use of regenerative
medicine to treat a wide variety of diseases with hPSC-derived
products in the near future.
4. Methods
4.1. Cell culture
The hiPSC cell lines, 253G1 [19], 201B7 [2], HiPS-RIKEN-1A (R-
1A), HiPS-RIKEN-2A (R-2A) and HiPS-RIKEN-12A (R-12A) were
provided by the RIKEN BRC through the Project for Realization of
Regenerative Medicine and the National Bio-Resource Project of the
MEXT, Japan. Undifferentiated hiPSCsweremaintained on Laminin-
521 (BioLamina, Stockholm) in Essential 8 medium (Invitrogen)
[16]. Colonies were passaged by dissociating the cells into single
cells once every 3e4 days using 0.5 mM EDTA in PBS at a density of
2  104 cells/cm2. Adult human cardiomyocytes (Promocell, Hei-
delberg) were cultured on Laminin-211 (BioLamina, Stockholm) in
the Promocell myocyte growth medium. Cells were grown in a
humidiﬁed atmosphere of 5% CO2 and 95% air at 37 C.
4.2. Cardiomyocyte differentiation of hiPSCs
Cardiomyocyte differentiation was induced as previously re-
ported, with a few modiﬁcations [11]. hiPSCs were detached by
incubationwith 0.5 mM EDTA in PBS for 7 min and seeded onto cell
culture plates coated with laminin-521 or Matrigel at a density of
50,000 cells/cm2 in Essential 8 or mTeSR1, respectively, for 3e4
days before cardiomyocyte induction. Conﬂuent hiPSCs were
treated with 12 mM CHIR99021 (Stemgent), a GSK3 inhibitor, in
RPMI1640 medium (SigmaeAldrich) supplemented with B27-
insulin (Invitrogen) (RPMI/B27-insulin) for 24 h. At day 1, the me-
diumwas changed to RPMI/B27-insulin. At day 3, cells were treated
with 5 mM IWP4 (Stemgent), a Wnt inhibitor, in RPMI/B27-insulin
for 48 h. At day 5, the medium was changed to RPMI/B27-insulin.
The cells were transferred to RPMI/B27without insulin at day 7, and
the medium was changed every 3 days. Differentiated cells were
harvested at the indicated time for further analysis.
4.3. qRT-PCR
Total RNAwas isolated from cells using an RNeasy Mini Kit with
DNase I treatment (Qiagen), according to the manufacturer's in-
structions. RNA concentration was determined using a Nanodrop
ND-1000 spectrophotometer (Thermo Fisher Scientiﬁc). In the
spike experiments, 253G1 cells and primary human car-
diomyocytes (PromoCell) were mixed at a deﬁned cell number
before RNA isolation. qRT-PCR was performed with the QuantiTect
Probe one-step RT-PCR Kit (Qiagen) on a 7300 Real-Time PCR Sys-
tem (Applied Biosystems). Total RNA (50 ng per sample) was used
for the analysis. The expression levels of target genes were
normalized to those of the GAPDH (glyceraldehyde-3-phosphate
dehydrogenase) transcript or ribosomal RNA, which were quanti-
ﬁed using TaqMan human GAPDH control reagents (Life Technol-
ogies) or TaqMan ribosomal RNA control reagents (Life
T. Kuroda et al. / Regenerative Therapy 2 (2015) 17e23 23Technologies). Probes labeled with 50-FAM/30-TAMRA and primers
were obtained from SigmaeAldrich. The sequences of primers and
probes used in the present study are listed in Table S1. All qRT-PCR
reactions were run at 45 cycles.4.4. Flow cytometry
253G1-derived cardiomyocytes were ﬁxed using the BD Cytoﬁx
ﬁxation buffer (BD Biosciences) for 20min and permeabilized using
BD Perm/Wash buffer (BD Biosciences) for 10 min at room tem-
perature. Cells were incubated for 1 h at room temperature with
mouse anti-tnnt2 monoclonal antibody (1:1000) (Abcam). Indirect
immunostaining was then completed with anti-mouse IgG Alexa
Fluor 488-conjugated secondary antibody (1:1000) (Molecular
Probes) for 1 h. Normal mouse IgG antibody was used as a negative
control (Millipore). Stained cells were analyzed using a BD FACS-
calibur II (BD Biosciences). Data retrieved from sorting was
analyzed using Flowjo software (Tree Star, Ashland, OR).4.5. One-step digital droplet PCR
Total RNA was prepared as described above. One-step droplet
digital PCR reaction mixtures (20 ml volume) were composed as
follows: 1  One-Step RT-ddPCR Supermix (Bio-Rad), 750 nM for-
ward and reverse primers, 250 nM probe labeled with 50-FAM/30-
BHQ-1, and 1 mM manganese acetate solution (Bio-Rad). Five ml of
total RNA sample (50 ng) was added to the mixture. The sequences
of primers and probes used in the present study are listed in
Table S2. Droplets were generated in 8-well cartridges using the
QX100 droplet generator (Bio-Rad) according to the manufacturer's
instructions. Water-in-oil emulsions were transferred to a 96-well
plate, and RT-PCR was performed using a T100™ thermal cycler
(Bio-Rad). Thermal cycling conditions were as follows: 30 min
reverse transcription at 60 C, followed by 5 min enzyme activation
at 95 C, and 40 cycles of a thermal proﬁle comprising 30 s dena-
turation at 94 C and 60 s annealing/extension at 64 C. After PCR
ampliﬁcation, products were denatured at 98 C for 10 min and
cooled at 4 C. Fluorescence intensities of each droplet from the
samples were measured using the QX100 droplet reader (Bio-Rad).
Positive droplets containing ampliﬁcation products were distin-
guished from negative droplets and counted by applying a ﬂuo-
rescence amplitude threshold in QuantaSoft software. The
threshold was manually determined at the highest point of the
sample droplet cluster of water and usually set at 3300 under our
experimental conditions. QuantaSoft software provides concen-
tration results in copies of target per microliter (copies/ml). The
number of copies of target per template RNA (i.e., copies/50 ng of
RNA) was calculated as concentration (copies/ml) x 20 (ml).4.6. Tissue RNA
Total RNA isolated from human heart, liver, pancreas, kidney,
spinal cord, and lung was obtained from Clontech Laboratories or
BioChain. Total RNA isolated from human corneal epithelium was
purchased from ScienCell Research Laboratories.Author contributions
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